Billerica, Mass. — Access Vascular Inc. and Medline have entered a multi-year agreement to expand access to next-generation midline and peripherally inserted central catheter products across U.S. hospitals.
Under the agreement, the companies will co-brand and co-develop products featuring Access Vascular’s HydroMID and HydroPICC catheters, which recently received an anti-thrombogenic indication from the Food and Drug Administration.
The products are expected to become available through Medline in late 2026 as part of fully assembled, customizable procedure kits. Distribution will include more than 1,600 health systems where Medline serves as the primary supplier of medical-surgical products.
Millions of midline and PICC catheters are placed annually in acute care settings, representing a market valued at more than $600 million. Many currently available products continue to rely on established polyurethane-based catheter technology.
Access Vascular’s catheters use a proprietary hydrogel material with anti-thrombogenic properties intended to help address complications such as thrombosis and occlusion, which can contribute to device replacements, hospital readmissions and higher health care costs.
The partnership combines Access Vascular’s biomaterial technology with Medline’s procedure-kitting, distribution and supply chain capabilities. The companies have a combined commercial and clinical presence of more than 300 acute care representatives, supported by a specialized vascular access team.
“Vascular access has needed a better solution for decades – we built a technology that significantly reduces device-replacement and complication rates based on real-world evidence, now we’re bringing it to hospitals across the U.S. with Medline,” said James Biggins, Chief Executive Officer of Access Vascular. “This partnership gives us the commercial reach to match our clinical ambition – from co-developing a customizable kitted solution to deploying it across a broad supply chain network. Most of all, I’m excited by how this accelerates our vision to bring innovation to clinicians and ultimately improve patient outcomes.”
“Reducing infection risk and improving catheter performance in vascular access has been a priority in our practice for years. Innovations that address those challenges — particularly without relying on chemical additives — are worth paying attention to,” said Matthew Ostroff, RN, MSN, AGACNP-BC, VABC, Vascular Access Coordinator at St. Joseph’s Health. “Solutions that can be scaled through broad distribution networks have the potential to set a new standard for performance and patient care, and that matters at the bedside every day. Collaborations like this have the potential to drive meaningful progress, giving clinicians the tools to reduce complications, improve efficiency, and consistently elevate the quality of care they deliver. That’s the kind of advancement our field needs.”
“Advancing vascular access requires both innovation and the ability to deliver it reliably at scale,” said Vish Bhave, executive vice president of Medline Brand. “This agreement allows us to pair clinically differentiated technology with our ability to deliver fully assembled, procedure-ready kits—helping health systems more seamlessly adopt solutions designed to address some of the most persistent challenges in vascular access.”
